Tenax Therapeutics, Inc.
NASDAQ:TENX · NASDAQ Capital Market
+$0.10 today
Vol 2.05M · Avg 0.62M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $118.8M |
| Other Current | $4.4M |
| Total Current Assets | $123.2M |
| Total Assets | $123.2M |
Analysis
Selected assets total $123.2M for Latest. The largest visible component is Cash & Equivalents at $118.8M, about 96.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $97.6M +2.9% | $94.9M +868.6% | $9.8M +361.1% | $2.1M -62.0% | $5.6M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $0 | $0 | $0 | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $1.0M +1492.2% | $64.0K -74.6% | $251.6K -27.3% | $345.9K +71605797101449376.0% | -$0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $104.2M +7.8% | $96.7M +727.5% | $11.7M +264.1% | $3.2M -43.6% | $5.7M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $0 | $0 | $0 -100.0% | $186.7K -36.7% | $294.8K | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $0 | $0 -100.0% | $1.1K -88.3% | $9.6K +13.2% | $8.4K | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $0 | $0 -100.0% | $1.1K -99.4% | $196.2K -35.3% | $303.2K | -$15.3B | $14.8B | $11.3B |
| Total Assets | $104.2M +7.8% | $96.7M +727.5% | $11.7M +243.2% | $3.4M -43.2% | $6.0M | $13.3B | $11.9B | $10.6B |
| Account Payables | $6.0M +91.4% | $3.2M +52.3% | $2.1M +362.3% | $448.4K -47.8% | $859.6K | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 -100.0% | $500.9K -19.8% | $624.3K | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $898.0K -32.8% | $1.3M +464.0% | $236.9K -3.5% | $245.4K | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $7.2M +52.5% | $4.7M +30.9% | $3.6M +94.1% | $1.8M +18.1% | $1.6M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $0 | $0 | $0 -100.0% | $64.2K -65.0% | $183.6K | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $7.2M +52.5% | $4.7M +30.9% | $3.6M +87.6% | $1.9M +9.4% | $1.7M | $14.7B | $3.7B | $9.6B |
| Common Stock | $1.0K | $0 -100.0% | $30 -99.3% | $4.6K +81.8% | $2.5K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$367.5M -16.7% | -$314.9M -5.9% | -$297.3M -2.7% | -$289.5M -4.0% | -$278.5M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 | $0 | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $97.1M +5.5% | $92.0M +1036.0% | $8.1M +442.5% | $1.5M -64.8% | $4.2M | $9.1B | $7.7B | $3.3B |
| Total Debt | $0 | $0 -100.0% | $500.9K -38.0% | $807.9K +177.8% | $290.8K | $724.2M | $410.6M | $399.4M |
| Net Debt | -$97.6M -2.9% | -$94.9M -920.9% | -$9.3M -606.1% | -$1.3M +75.1% | -$5.3M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Q32 Bio Inc.
NASDAQ:QTTB
$161.43M
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$134.68M
Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
$62.15M
SAB Biotherapeutics, Inc.
SABS
$37.92M
Boundless Bio, Inc.
BOLD
$31.90M
Minerva Neurosciences, Inc.
NERV
$29.44M
Pluri Inc.
PLUR
$19.78M
Plus Therapeutics, Inc.
PSTV
$10.19M
Jasper Therapeutics, Inc.
JSPR
$7.49M
NextCure, Inc.
NXTC
$5.47M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does TENX have?
Tenax Therapeutics, Inc. (TENX) reported $97.56M in cash and equivalents in fiscal 2025.
How much debt does TENX carry?
Tenax Therapeutics, Inc. (TENX) reported $0.00 of total debt, with net debt of -$97,565,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.